Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

666

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Vaccines, Pneumococcal
Interventions
BIOLOGICAL

13 valent pneumococcal conjugate vaccine

1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.

BIOLOGICAL

7vPnc pneumococcal conjugate vaccine

1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.

Trial Locations (37)

10467

The Bronx

14620

Rochester

15090

Wexford

15227

Pittsburgh

15236

Pittsburgh

15241

Pittsburgh

15650

Latrobe

18960

Sellersville

22180

Vienna

23219

Richmond

29425

Charleston

30062

Marietta

30189

Woodstock

33606

Tampa

38305

Jackson

40004

Bardstown

40202

Louisville

40207

Louisville

44118

Cleveland

45040

Mason

45245

Cincinnati

60068

Park Ridge

60612

Chicago

66212

Overland Park

72205

Little Rock

72401

Jonesboro

72703

Fayetteville

77380

The Woodlands

80112

Centennial

84107

Murray

84604

Provo

90242

Downey

90723

Paramount

92335

Fontana

92354

Loma Linda

92505

Riverside

06360

Norwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00373958 - Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter